Ensysce Biosciences Fully Enrolls Part 2 of PF614-MPAR-102 Study, Advancing Overdose-Protected Opioid Development

Reuters06-24

Ensysce Biosciences Fully Enrolls Part 2 of PF614-MPAR-102 Study, Advancing Overdose-Protected Opioid Development

Ensysce Biosciences Inc., a clinical-stage pharmaceutical company, has announced the full enrollment of Part 2 of the PF614-MPAR-102 clinical study. This phase of the study aims to examine the effect of food on the company's MPAR technology, which is designed to enhance opioid safety. The PF614-MPAR, which has been awarded the FDA's Breakthrough Therapy designation, incorporates Ensysce's proprietary TAAP™ and MPAR® technologies to provide overdose protection while maintaining pain relief efficacy. The study is supported by a three-year grant from the National Institute on Drug Abuse, with funding secured through May 2027. Results of this clinical trial have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1042177) on June 24, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2545284760?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-24 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545284760","market":"us","top_or_hot":-1,"title":"Ensysce Biosciences Fully Enrolls Part 2 of PF614-MPAR-102 Study, Advancing Overdose-Protected Opioid Development","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ensysce Biosciences Fully Enrolls Part 2 of PF614-MPAR-102 Study, Advancing Overdose-Protected Opioid Development\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ENSC\">Ensysce Biosciences Inc.</a>, a clinical-stage pharmaceutical company, has announced the full enrollment of Part 2 of the PF614-MPAR-102 clinical study. This phase of the study aims to examine the effect of food on the company's MPAR technology, which is designed to enhance opioid safety. The PF614-MPAR, which has been awarded the FDA's Breakthrough Therapy designation, incorporates Ensysce's proprietary TAAP™ and MPAR® technologies to provide overdose protection while maintaining pain relief efficacy. The study is supported by a three-year grant from the National Institute on Drug Abuse, with funding secured through May 2027. Results of this clinical trial have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ENSCW\">Ensysce Biosciences Inc.</a> published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1042177) on June 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ensysce Biosciences Fully Enrolls Part 2 of PF614-MPAR-102 Study, Advancing Overdose-Protected Opioid Development</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEnsysce Biosciences Fully Enrolls Part 2 of PF614-MPAR-102 Study, Advancing Overdose-Protected Opioid Development\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-24 20:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ensysce Biosciences Fully Enrolls Part 2 of PF614-MPAR-102 Study, Advancing Overdose-Protected Opioid Development\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ENSC\">Ensysce Biosciences Inc.</a>, a clinical-stage pharmaceutical company, has announced the full enrollment of Part 2 of the PF614-MPAR-102 clinical study. This phase of the study aims to examine the effect of food on the company's MPAR technology, which is designed to enhance opioid safety. The PF614-MPAR, which has been awarded the FDA's Breakthrough Therapy designation, incorporates Ensysce's proprietary TAAP™ and MPAR® technologies to provide overdose protection while maintaining pain relief efficacy. The study is supported by a three-year grant from the National Institute on Drug Abuse, with funding secured through May 2027. Results of this clinical trial have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ENSCW\">Ensysce Biosciences Inc.</a> published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1042177) on June 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nNDL6N5K0q:1","article_id":"2545284760","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545284760","pubTimestamp":1750766737,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ensysce Biosciences Inc., a clinical-stage pharmaceutical company, has announced the full enrollment of Part 2 of the PF614-MPAR-102 clinical study. This phase of the study aims to examine the effect of food on the company's MPAR technology, which is designed to enhance opioid safety. The PF614-MPAR, which has been awarded the FDA's Breakthrough Therapy designation, incorporates Ensysce's proprietary TAAP and MPAR technologies to provide overdose protection while maintaining pain relief efficacy. The study is supported by a three-year grant from the National Institute on Drug Abuse, with funding secured through May 2027. Results of this clinical trial have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce B","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ENSC":"Ensysce Biosciences Inc."},"translate_title":"Ensysce Biosciences全面纳入PF614-MPAR-102研究的第2部分，推进用药过量保护阿片类药物的开发","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ENSC":0.9},"content_text":"Ensysce Biosciences Fully Enrolls Part 2 of PF614-MPAR-102 Study, Advancing Overdose-Protected Opioid Development\n    \n\nEnsysce Biosciences Inc., a clinical-stage pharmaceutical company, has announced the full enrollment of Part 2 of the PF614-MPAR-102 clinical study. This phase of the study aims to examine the effect of food on the company's MPAR technology, which is designed to enhance opioid safety. The PF614-MPAR, which has been awarded the FDA's Breakthrough Therapy designation, incorporates Ensysce's proprietary TAAP™ and MPAR® technologies to provide overdose protection while maintaining pain relief efficacy. The study is supported by a three-year grant from the National Institute on Drug Abuse, with funding secured through May 2027. Results of this clinical trial have not yet been presented.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1042177) on June 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2545284760","isCrawlerRequest":true}